CLAIMS

1. Use of lenvatinib or a pharmacologically acceptable salt thereof for the manufacture of a pharmaceutical composition for treating a tumor, wherein lenvatinib or the pharmacologically acceptable salt thereof is to be administered in combination with ifosfamide and etoposide or a pharmacologically acceptable salt thereof.

2. The use according to claim 1, wherein the lenvatinib or a pharmacologically acceptable salt thereof is lenvatinib mesylate.

3. The use according to any one of claims 1 to 2, wherein the etoposide or a pharmacologically acceptable salt thereof is etoposide phosphate.

4. The use according to any one of claims 1 to 3, wherein the lenvatinib or a pharmacologically acceptable salt thereof, ifosfamide, and etoposide or a pharmacologically acceptable salt thereof are to be administered simultaneously, separately, continuously, or at time intervals.

5. The use according to any one of claims 1 to 4, wherein the tumor is osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma, retinoblastoma, hepatoblastoma, or nephroblastoma.

6. The use according to claim 5, wherein the tumor is osteosarcoma.

7. The use according to claim 6, wherein the osteosarcoma is relapsed or refractory.